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partially ameliorated by simvastatin but significantly improvedEffect of combining ACE inhibitor and statin in severe experi-
by combined therapy. Drug combination significantly limitedmental nephropathy.
glomerulosclerosis, tubular damage and interstitial inflamma-Background. Angiotensin-converting enzyme (ACE) inhib-
tion, compared to vehicle or drugs alone. Up-regulation ofitor therapy given soon after disease induction uniformly pre-
monocyte chemoattractant protein-1 (MCP-1) mRNA in PHNvents proteinuria in virtually all models of disease progression.
kidneys was not affected by lisinopril, it was inhibited by 30%This does not necessarily apply to patients with proteinuric
after simvastatin, and almost completely normalized by lisino-nephropathies, who might be referred late in the course of
pril plus simvastatin.their disease. Here we used a severe rat model of passive
Conclusions. These data suggest that a combined ACE in-Heymann nephritis (PHN), which may mimic advanced phases
hibitor and statin approach could represent a therapeutic op-of human membranous nephropathy, to study the response to
tion for patients with advanced renal disease in whom ACEACE inhibitor alone or in combination with a HMG CoA
inhibitors alone fail to lower proteinuria and injury to anyreductase inhibitor (statin) that independently of the choles-
substantial extent.terol-lowering effect influences pathways involved in inflam-
matory and fibrogenic processes. Therapies started when ani-
mals had massive proteinuria and renal lesions.
Methods. PHN was accelerated by uninephrectomy seven
Progression to renal parenchymal damage and end-days after IV injection of rabbit anti-FX1A antibody. Four
stage renal failure is the final common pathway of chronicmonths later, when massive proteinuria and renal lesions were
present, the rats were divided into five groups and daily given proteinuric nephropathies in animals and humans, and
orally: vehicle; lisinopril 40 mg/L; lisinopril 400 mg/L; simvas- appears to be largely independent of the type of initial
tatin 2 mg/kg b.i.d; or lisinopril 40 mg/L plus simvastatin. Six insult. Pathogenetic factors include altered glomerular
normal rats served as controls. Animals were sacrificed at 10
permeability to proteins, which are then filtered in exces-months.
sive quantities to reach the lumen of proximal tubuli.Results. By the end of the study three PHN rats died in the
vehicle group, four in the group given lisinopril at 40 mg/L and The reabsorption of filtered proteins can contribute to
two in the group at 400 mg/L, whereas all rats on simvastatin or renal interstitial injury by activating proximal tubular
combined therapy were alive. Blood pressure increased during cell to behave like an inflammatory cell [1]. Evidence
time in PHN and was normalized by treatment with ACE
is indeed available that the nuclear transcription factorinhibitor and combined therapy. Even at the high dose lisinopril
NF-B is activated in proximal tubular cells in conditionsfailed to reduce proteinuria. Simvastatin only partially affected
proteinuria. However, combining lisinopril with simvastatin of increased protein traffic [2–4], which serves to enhance
had a remarkable antiproteinuric effect, such that at 10 months monocyte chemoattractant protein-1 (MCP-1) gene tran-
the urinary proteins were comparable to pre-treatment values scription, whose protein product has potent chemotacticand significantly lower than either the vehicle or lisinopril
and inflammatory activity in the tubulointerstitial com-groups. Hypercholesterolemia of PHN rats was limited by com-
partment [5]. Interstitial inflammation and disease pro-bined therapy, and a positive correlation was found between
serum cholesterol and proteinuria. Renal function was only gression are both limited by the enhanced glomerular
permselective function, which effectively limits protein-
dependent signaling for interstitial cell infiltration and
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extracellular matrix deposition [6].therapy, progressive renal disease, angiotensin converting enzyme in-
hibitor. In virtually all experimental models of disease progres-
sion, blockade of the renin-angiotensin system by angio-Received for publication June 5, 2001
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soon after disease induction [7–10]. This does not neces- were used in this study. Animal care and treatment were
sarily apply to patients with proteinuric nephropathies conducted in accordance with the institutional guidelines
who are usually referred much later in the course of that are in compliance with national (Decreto Legislativo
their disease. n.116, Gazzetta Ufficiale suppl 40, 18 febbraio 1992, Cir-
Lipid abnormalities have been implicated in the pro- colare n.8, Gazzetta Ufficiale 14 luglio 1994) and interna-
gression of renal disease [11]. Using the remnant kidney tional laws and policies (EEC Council Directive 86/609,
model in rats, Kasiske et al showed that increasing serum OJL358-1, December 1987; Guide for the Care and Use
cholesterol concentration with cholesterol feeding ac- of Laboratory Animals, U.S. National Research Council,
celerated the development of progressive renal lesions 1996). All animals were housed in a room in which the
[12]. Treatment with lipid-lowering agents, namely the temperature was kept constant on a 12-hour dark/12-
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) hour light cycle and allowed free access to standard diet
reductase inhibitors, or statins, by blocking mevalonate containing 20% protein by weight and tap water. PHN
production and thus the rate-limiting step in cholesterol was induced in non-anesthetized rats by a single intrave-
biosynthesis, ameliorated renal function and structure in nous injection of 0.4 mL/100 g body wt of rabbit anti-
several rat models of progressive renal diseases, includ- Fx1A antibody. Unilateral nephrectomy at day 7, when
ing 5/6 nephrectomy [13], obese Zucker rats [14], strep-
animals are proteinuric, was performed to accelerate thetozotocin-induced diabetes [15] and puromycin-induced
onset of renal histological damage without exacerbatingnephrotic syndrome [16, 17]. Suppression of mesangial
hypertension [26]. Four months later, animals underwentcell proliferation and macrophage infiltration was achieved
renal biopsy. A small portion of the upper pole of thein rats with mesangial proliferative nephritis [18]. How-
kidney was surgically removed, and bleeding from theever, statins’ effects exceeded what could be expected on
biopsy wound controlled with application of gelform. Thethe basis of improvement of dyslipidemia per se, and re-
renal tissue thus obtained was processed for histologicalcent evidence has shown its direct influence on important
examination as described below. Rats were then dividedintracellular signaling systems involved in cell prolifera-
into five groups with equal average glomerular and tubu-tion, inflammatory and fibrogenic responses [19]. Statins
lointerstitial changes and daily treated up to 10 monthshave been reported to reduce in vitro proliferation of
as follows: vehicle (group 1, N  8); lisinopril (Merckmesangial cells [20] and of tubular epithelial cells [21],
Sharp & Dohme Italia, Rome, Italy) 40 mg/L in theto inhibit expression of chemokines such as MCP-1 [22],
drinking water (group 2, N  8); lisinopril 400 mg/Land to modulate mRNAs coding for transforming growth
(group 3, N  8); simvastatin (Merck Sharp & Dohmefactor- (TGF-) and matrix components [15, 23]. These
effects result from the modification of signal transduction Italia) 2 mg/kg b.i.d (group 4, N  6); and lisinopril 40
proteins by geranylgeranyl- or farnesyl-pyrophosphates mg/L plus simvastatin 2 mg/kg b.i.d by gavage (group 5,
generated by the mevalonate pathway [24]. Actually, N  8). Doses of lisinopril (for group 2) and simvastatin
statins interfere with prenylation of Ras and Rho family were chosen on the basis of previously published studies
small guanine 5-triphosphate (GTP)-binding proteins, [10, 18]. In group 3 rats, the final dose of 400 mg/L
thereby blocking the activation of mitogen-activated pro- lisinopril was reached by incremental increases (50 mg/
tein kinase (MAPK) signaling pathways and various L/week) in the dose over the first month, beginning with
transcription factors including NF-B [19, 23], which reg- 200 mg/L. An additional group of normal rats served as
ulates the expression of inflammatory, vasoactive and control (group 6, N 6). Systolic blood pressure, urinary
fibrogenic genes critical to renal disease progression [25]. protein excretion and serum creatinine were measured
The present studies have been done in a severe disease every two months. Serum levels of cholesterol, triglycer-
model, accelerated passive Heymann nephritis (PHN) ides, aspartate transaminase (AST) and alanine amino-
in the rat [26], which may mimic advanced phases of transferase (ALT) were assessed at month 4 (before
human membranous nephropathy. We sought to investi- treatment) and at the end of the study. At month 10,
gate the response to ACE inhibitor alone—given in in- rats were anesthetized and kidneys were removed for
creasing doses—or in combination with simvastatin.
histology, immunohistochemistry, Northern blot analy-Treatment was started when the animals had already
sis, and in situ hybridization for MCP-1 mRNA expres-massive proteinuria and renal lesions. Outcome parame-
sion. At this time no difference was found in the fixationters included blood pressure level, the magnitude of pro-
of rabbit FX1A antibody to glomerular capillary walls byteinuria, the degree of renal function and glomerular
indirect immunofluorescence analysis on kidneys fromand tubulointerstitial changes at 10 months.
PHN rats given vehicle (N  3) or treated with lisinopril
plus simvastatin (N  6).
METHODS Systolic blood pressure (SBP) was recorded by tail
Experimental design plethysmography in conscious rats [27]. Twenty-four-hour
urine samples were collected using metabolic cages andMale Sprague-Dawley rats (Charles River Italia s.p.a.,
Calco, Italy) with initial body weights of 300 to 350 g proteinuria was determined by modified Coomassie blue
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G dye-binding assay for proteins with bovine serum albu- 10 randomly selected high power microscopic fields
(400) per each animal.min (BSA) as the standard [28]. Blood was collected
from the tail vein of anesthetized animals. Serum was
Northern blot analysisobtained after whole blood clotting and kept frozen at
20C until assayed. Creatinine was measured by alka- Total RNA was isolated from whole kidney tissue by
the guanidium isothiocyanate/cesium chloride proce-line picrate method [29]. Serum cholesterol, triglycer-
ides, and transaminase levels were measured using an dure, as previously described [31]. Twenty micrograms
of total RNA were then fractionated on 1.6% agaroseautoanalyzer (CX5; Beckman Instruments Inc., Fuller-
ton, CA, USA). gel and blotted onto synthetic membranes (Zeta-probe;
Biorad, Richmond, CA, USA). Plasmid containing mu-
Renal histology rine JE/MCP-1 probe was kindly provided by Dr. Charles
D. Stiles (Harvard Medical School and Dana-Faber Can-The removed kidneys were fixed for six hours in Du-
bosq-Brazil, dehydrated in alcohol, and embedded in cer Institute, Boston, MA, USA). MCP-1 mRNA was de-
tected by using the 577 base pair (bp) of a MCP-1 cDNA.paraffin. Kidney samples were sectioned at 3 m inter-
vals and the sections were stained with Masson’s tri- The probes were labeled with 	-32P dCTP by the random-
primed method as previously described [4]. Hybridiza-chrome, hematoxylin and eosin, and periodic-acid Schiff
reagent (PAS stain). Tubular (atrophy, casts, and dila- tion was performed overnight in 0.5 mol/L Na2HPO4,
pH 7.2, 7% sodium dodecyl sulfate (SDS). Filters weretion) and interstitial changes (fibrosis and inflammation)
were graded from 0 to 4
: 0 no changes; 1
 changes washed twice for 30 minutes with 40 mmol/L Na2HPO4,
pH 7.2, 5% SDS and two times for 10 minutes with 40affecting less than 25% of the sample; 2
  changes
affecting 25 to 50% of the sample; 3
  changes affect- mmol/L Na2HPO4, pH 7.2, 1% SDS at 65C. Membranes
were subsequently probed with a glyceraldehyde-3-phos-ing 50 to 75% of the sample; 4
  changes affecting 75
to 100% of the sample). At least 100 glomeruli were phate dehydrogenase (GAPDH) cDNA, taken as inter-
nal standard of equal loading of the samples on the mem-examined for each animal and the extent of glomerular
damage was expressed as the percentage of glomeruli brane. MCP-1 mRNA optical density was normalized
to that of the constituently released GAPDH gene ex-presenting sclerotic lesions. All renal biopsies were ana-
lyzed by the same pathologist who was unaware of the pression.
nature of the experimental groups.
In situ hybridization
Immunohistochemical analysis In situ hybridization experiments for MCP-1 mRNA
were performed as previously described [4]. The murineMouse monoclonal antibodies were used for the im-
munohistochemical detection of the following antigens: MCP-1 antisense and sense RNA probes were prepared
and labeled by in vitro transcription using digoxigenin-ED-1 antigen present in rat monocytes and macrophages
(Chemicon, Temecula, CA, USA); CD4
 cell surface labeled uridine triphosphate (Roche Diagnostics s.p.a,
Monza, Italy). A 577 bp murine MCP-1 cDNA was clonedglycoprotein, a 55-kD molecule expressed by helper
T cells, thymocytes, and macrophages (W3/25; Valter into the EcoRI site of the pGEM-1 vector between SP6
and T7 promoters. Fragments of renal cortex were fixedOcchiena srl, Torino, Italy); rat CD8
 cell surface glyco-
protein expressed by T-suppressor cells (OX8; Phar- in Dubosq-Brazil, dehydrated in alcohol, and embedded
in paraffin. Sections were cut at 4 m and after perme-Mingen, Los Angeles, CA, USA); and a rat MHC class
II antigen monomorphic determinant (OX6; Valter Oc- abilization with proteinase K (40 g/mL; Sigma), they
were hybridized with the RNA probes at the final con-chiena). Detection of ED-1 and CD8 antigens was per-
formed on paraffin sections using an alkaline phospha- centrations of 0.2 ng/L in 2  standard sodium citrate
(SSC), 10% dextran sulfate, 1  Denhardt’s solution,tase-Fast Red technique as previously described [30].
CD4 and MHC class II antigens were analyzed by indi- 20 mmol/L Vanadyl Ribonucleoside Complex (GIBCO
BRL, Life Technologies, Gaithersburg, MD, USA), 0.1rect immunofluorescence technique. Fragments of renal
tissues were frozen in liquid nitrogen and cut at 5 m mol/L sodium phosphate and incubated overnight in a
moist chamber at 55C. After being washed in 0.2 SSCusing a Mikrom 500 O cryostat (Walldorf, Germany).
The sections were blocked with 1% phosphate-buffered and blocked with a buffer blocking solution (50 mg/mL
skimmed dried milk, 150 mmol/L NaCl in 100 mmol/Lsaline (PBS)/BSA, incubated overnight at 4C with the
primary antibody (W3/25, 40 g/mL; OX6, 5 g/mL), Tris-HCl, pH 7.8) at room temperature for 30 minutes,
the sections were incubated with anti-digoxigenin anti-washed with PBS, and then incubated with Cy3-con-
jugated donkey anti-mouse IgG antibodies (5 g/mL body conjugated with alkaline phosphatase (Roche)
at the dilution of 1:1000 for 45 minutes at 37C. Colori-in PBS; Jackson ImmunoResearch Laboratories, West
Grove, PA, USA) for one hour at room temperature. metric detection with nitro blue tetrazolium salt and
5-bromo-4-chloro-3-indolyl phosphate (Roche) was thenFor each marker, positive cells were counted in at least
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performed, and the sections were mounted in 60% glyc-
erol and examined by light microscopy. The negative
control included hybridization step with the sense probe.
Statistical analysis
Data are expressed as mean SE. Data were analyzed
using the non-parametric Kruskal-Wallis test for multi-
ple comparisons. Linear regression analysis was per-
formed between systolic blood pressure and proteinuria
or serum creatinine or renal damage (glomerulosclerosis,
tubular damage, interstitial inflammation), and between
proteinuria and serum cholesterol or triglycerides. The
statistical significance level was defined as P  0.05.
RESULTS
By the end of the study three PHN rats died in the
vehicle group, four in the group given lisinopril 40 mg/L,
and two in the group given the high dose of lisinopril (400
mg/L), while all rats on simvastatin alone or combined
therapy were alive.
Fig. 1. Systolic blood pressure measured at months 4 [() control; ( )Food intake and body weight
PHN; before treatment] and 10 after disease induction, in PHN rats
Food intake was comparable in all PHN and control given vehicle (), or lisinopril at the doses of 40 mg/L (lis 40; ) and
400 mg/L (lis 400; ), or simvastatin (simv; ), or the combination ofrats for the entire study period. The average food intake
lisinopril 40 mg/L plus simvastatin (lis 40 
 simv; ), and in controlat month 10 was as follows: PHN
 vehicle, 25  1 g/day; rats (). Data are mean  SE. * P  0.01 vs. control; P  0.01 vs.
PHN
 lisinopril 40 mg/L, 27 0.2 g/day; PHN
 lisino- vehicle; § P  0.01 vs. lisinopril 40 and 400 mg/L; # P  0.01 vs. vehicle
and simvastatin; 
P  0.05 vs. control.pril 400 mg/L, 26  0.3 g/day; PHN 
 simvastatin, 25 
2 g/day; PHN 
 lisinopril 
 simvastatin, 26  1 g/day;
control, 24 1 g/day. All PHN gained weight in a similar
manner and at the end of the study body weight values rum creatinine (r 0.40, P 0.05), no significant correla-
were comparable (vehicle 613  32 g; lisinopril 40 mg/L, tion was found between SBP and functional and struc-
598  11 g; lisinopril 400 mg/L, 588  26 g; simvastatin, tural changes including proteinuria (r  0.184, P 
603  31 g; lisinopril 
 simvastatin, 597  15 g). Body 0.289), glomerulosclerosis (r 0.276, P 0.105), tubular
weights of control rats were numerically higher than damage (r 0.186, P 0.292), and interstitial inflamma-
those of PHN rats, although a statistical significance was tion (r  0.220, P  0.210).
not reached (670  17 g).
Urinary protein excretion
Systolic blood pressure At month 4, before treatments, PHN rats had high
As shown in Figure 1, PHN animals were normoten- levels of urinary protein excretion (492  20 mg/day,
sive until four months after disease induction (PHN, N 38). In animals given vehicle proteinuria augmented
135  2; control, 121  2 mm Hg). Then they exhibited during time averaging 718  100 mg/day at month 10
an increase in SBP, which averaged 156  5 mm Hg at (Fig. 2). Lisinopril failed to reduce proteinuria, even at
the end of the study (P  0.01 vs. control, 130  1 the high dose (40 mg/L, 792  38 mg/day; 400 mg/L,
mm Hg). Treatment with lisinopril alone or combined 661  107 mg/day). In rats given simvastatin alone uri-
with simvastatin controlled SBP, with values being sig- nary protein excretion values were numerically lower—
nificantly (P  0.01) lower than those of vehicle-rats although not different—from those of the vehicle group
(lisinopril 40 mg/L, 117  7; lisinopril 400 mg/L, 119  (601  84 mg/day). By contrast, combining lisinopril (40
6; lisinopril
 simvastatin, 106 5 mm Hg). In rats given mg/L) with simvastatin had a remarkable antiproteinuric
the combined therapy SBP levels were even lower (P  effect, to the extent that in four out of eight animals
0.05) than those of control rats. In PHN rats treated urinary proteins at 10 months were less than at 4 months,
with simvastatin alone SBP values tended to be lower and in three rats levels remained stable during time,
than those of PHN given vehicle (simvastatin, 141  4 whereas only one rat did not respond to therapy. As
mm Hg). shown in Figure 2, in this group, at the end of the study,
mean value of proteinuria was comparable to that mea-Except than a weak correlation between SBP and se-
Zoja et al: ACEi plus statin in progressive nephropathy 1639
Fig. 3. Serum creatinine levels measured at months 4 [() control;
( ) PHN; before treatment] and 10 after disease induction, in PHNFig. 2. Urinary protein excretion measured at months 4 (before treat-
rats given vehicle () or lisinopril at the doses of 40 mg/L (lis 40; )ment) and 10 after disease induction, in PHN rats given vehicle (), or
and 400 mg/L (lis 400, ), or simvastatin (simv; ), or the combinationlisinopril at the doses of 40 mg/L (lis 40; ) and 400 mg/L (lis 400; ),
of lisinopril 40 mg/L plus simvastatin (lis 40 
 simv; ) and in controlor simvastatin (simv; ), or the combination of lisinopril 40 mg/L
rats. Data are mean  SE. P  0.01 versus control; # P  0.01 versusplus simvastatin (lis 40 
 simv; ( ), and in control rats (). Data are
other PHN groups.mean  SE. P  0.01 vs. control; * P  0.05 vs. vehicle and lisinopril
40 mg/L.
Table 1. Serum lipid profile and transaminase levels
Serum cholesterol Serum triglycerides ALT AST
Groups mg/dL IU/L
PHN 
 vehicle 15122a 30033a 413 8610
PHN 
 lisinopril 40 mg/L 24615a,b 46275a,c 321 622
PHN 
 lisinopril 400 mg/L 15321a 24345 345 638
PHN 
 simvastatin 4 mg/kg 13722a 34256a 463 734
PHN 
 lis 40
 simvastatin 12616a 23545 432 865
Control 705 15122 586 9312
Values are mean  SE. Measurements were performed at month 10.
a P  0.05 vs. control
b P  0.05 vs. other PHN groups
c P  0.05 vs. lisinopril 400 mg/L and combined therapy
sured before treatment and it was significantly (P 0.05) rats on lisinopril 
 simvastatin therapy the serum creati-
nine value at 10 months (0.82  0.04 mg/dl) was fairlyreduced compared to rats treated with vehicle.
comparable to that measured in the same animals before
Renal function treatment (0.93  0.03 mg/dL), and it was significantly
(P  0.01) lower than in other PHN groups.Renal function in PHN rats was already impaired at
4 months and worsened at 10 months, as indicated by
Serum cholesterol and triglyceridesserum creatinine levels significantly (P  0.01) higher
than controls (month 4, 0.99 0.02 vs. 0.65 0.01 mg/dL; In PHN rats the serum cholesterol level increased over
time with respect to controls (month 4, 132 11 vs. 58month 10, 1.54  0.24 vs. 0.69  0.02 mg/dL; Fig. 3).
Lisinopril at both doses did not affect renal function (40 4 mg/dL; month 10, 151  22 vs. 70  6 mg/dL, P 
0.05). As shown in Table 1, treatment with lisinopril didmg/L, 1.55  0.15 mg/dL; 400 mg/L, 1.65  0.08 mg/
dL). In PHN rats treated with simvastatin mean value not ameliorate hypercholesterolemia. In the simvastatin
group mean value of serum cholesterol tended to beof serum creatinine tended to be lower than in rats given
vehicle or lisinopril (1.32  0.16 mg/dL), although a lower than in vehicle-treated rats. This tendency was
more evident in animals on lisinopril plus simvastatinstatistical significance was not achieved. By contrast, in
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Fig. 4. Linear regression analysis of relationship between proteinuria
and serum cholesterol performed at 10 months in PHN and control
rats (r  0.85, P  0.001).
therapy. Interestingly, in those four out of eight rats that
showed a reduction in proteinuria with respect to pre-
treatment levels, serum cholesterol accounted for values
within the control range.
A positive significant correlation (r 0.85, P  0.001)
was found between serum cholesterol and urinary pro-
tein excretion (Fig. 4).
Serum triglycerides also correlated with proteinuria,
but to a lesser extent (r  0.63, P  0.001), probably due
to the wide variability of values, as shown in Table 1.
Serum transaminase levels
As depicted in Table 1, treatment with lisinopril alone
or in combination with simvastatin did not modify serum
ALT and AST levels, which were comparable among all
of the experimental groups.
Renal histology
The results of the morphological evaluation at biopsy
(month 4) and autopsy (month 10) are reported in Fig-
ure 5. At four months, either the percentage of sclerotic
glomeruli or the score of tubular damage and interstitial
inflammation were significantly increased in PHN rats
over controls, and were similar at this time among the
five PHN groups by study design. At 10 months, in PHN
rats given vehicle, focal and segmental glomerulosclero-

Fig. 5. Renal morphological parameters on biopsies taken at months
4 (before treatment) and 10 after disease induction, in PHN rats given
vehicle (), or lisinopril at the doses of 40 mg/L (lis 40; ) and 400
mg/L (lis 400; ), or simvastatin (simv; ), or the combination of
lisinopril 40 mg/L plus simvastatin (lis 40 
 simv; ) and in control
rats (). Data are mean  SE. P  0.01 vs. control; # P  0.01 vs.
vehicle and simvastatin; 
P 0.05 vs. lisinopril 40 and 400 mg/L; § P
0.01 vs. vehicle, lisinopril 40 and 400 mg/L.
Zoja et al: ACEi plus statin in progressive nephropathy 1641
Table 2. Effect of lisinopril, simvastatin, and their combination on
immunostaining of interstitial ED1
 macrophages, CD4
 and
CD8
 cells, and OX6
 (MHC II) cells
Groups ED-1
 CD4
 CD8
 OX6

PHN 
 vehicle 543b 857a 283b 995a
PHN 
 lisinopril 40 mg/L 484a 1006a 213b 1022a
PHN 
 lisinopril 400 mg/L 496a 925a 244b 986a
PHN 
 simvastatin 4 mg/kg 436a 866a 176a 8210a
PHN 
 lis 40
 simvastatin 264a,d,e 625a,f 172a,c 676a,c,g
Control 92 443 21 282
Values are mean  SE (cells/high-power field).
a P  0.05
b P  0.01 vs. control
c P  0.05
d P  0.01 vs. vehicle
e P  0.05 vs. lisinopril 40 and 400 mg/L and simvastatin
f P  0.05 vs. other PHN groups
g P  0.05 vs. lisinopril 40 and 400 mg/L
sis affected on average 68% of glomeruli, with a fourfold
increase in percentage of sclerotic glomeruli from biopsy
to autopsy. Tubulointerstitial changes consisted of inter-
stitial fibrosis and inflammation associated with tubular
atrophy and large eosinophilic casts in the tubular lumen.
Scores for tubular damage and interstitial inflammation
averaged 2.5 and 3.0, respectively. Both doses of lisino-
pril had no effect on glomerular and tubulointerstitial
changes. In simvastatin treated rats, glomerulosclerosis
and tubular damage were comparable to vehicle-group,
whereas interstitial inflammation tended to be less se-
vere. Remarkably, in rats given the combined therapy
glomerulosclerosis and tubulointerstitial changes were
Fig. 6. (Top) Renal expression of MCP-1 mRNA assessed at month 10
dramatically reduced to statistically significant extent in age-matched control rats and in PHN rats given vehicle, or lisinopril at
the doses of 40 mg/L (lis 40) and 400 mg/L (lis 400), or simvastatincompared to the PHN rats given vehicle or drugs alone.
(simv), or the combination of lisinopril 40 mg/L plus simvastatin (lis 40
Thus, sclerotic changes in this group were confined on
simv). Northern blot experiments were performed using total RNA
average to 31% of glomeruli (1.8-fold increase in % of from whole kidney tissue of either separate or pooled samples for each
group. Results shown are representative of pooled samples for eachsclerotic glomeruli from biopsy to autopsy) and the score
group. (Bottom) Densitometric analysis of the autoradiographic signalsfor tubular damage and interstitial inflammation aver-
for MCP-1. Results shown are mean  SE of separate animals for
aged 1.0. each group. The optical density of the autoradiographic signals was
quantitated and calculated as the ratio of MCP-1 to GAPDH mRNA.
Results expressed as fold increase over control (represented as 1) inInflammatory cell infiltrates in renal interstitium
densitometric arbitrary units. P  0.05 vs. control; # P  0.05 vs.
Data of the analysis of inflammatory cell infiltrates control, vehicle and lisinopril 40 mg/L; * P 0.01 vs. other PHN groups.
into the renal interstitium are shown in Table 2. Com-
pared with controls, high numbers of ED-1 positive
monocytes/macrophages, CD-4 positive T-cells/macro-
Renal expression of MCP-1 mRNAphages, CD-8 positive T-cells, and OX-6 (MHC-II) posi-
tive cells were detected in the interstitium of PHN rats Consistent with our previous study [4], up-regulation
given vehicle, as evaluated at the end of the study. Ad- of MCP-1 mRNA was observed in the kidney of PHN
ministration of lisinopril at both doses did not substan- rats given vehicle with respect to age-matched controls
tially affect the numbers of infiltrating cells. A tendency (Fig. 6). MCP-1 transcripts were still elevated after lisino-
toward a less accumulation of ED-1, CD-8 and MHC- pril treatment. In the rats given simvastatin MCP-1 gene
II positive cells was observed in the renal interstitium up-regulation was inhibited by 30% with respect to vehi-
of rats treated with simvastatin alone with respect to cle, whereas the MCP-1 signal appeared almost completely
vehicle-treated rats, although a statistical significance normalized after lisinopril plus simvastatin therapy.
was not reached. By contrast, the degrees of cell infil- In situ hybridization experiments using antisense MCP-1
trates were significantly limited by the combined therapy, RNA probe were performed on kidney tissue from con-
trol rats, PHN rats given vehicle or treated with the com-as compared to animals given vehicle or drugs alone.
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Fig. 7. Photomicrographs showing MCP-1
mRNA expression by in situ hybridization in
kidneys from a control rat (a), a rat with PHN
given vehicle (b), and a rat with PHN treated
with lisinopril plus simvastatin (c) at 10 months
(digoxigenin d-UTP-labeled murine MCP-1
RNA probe, alkaline phosphatase reporter
system). (d) Negative control using MCP-1
sense RNA probe in a kidney section of PHN
rat plus vehicle adjacent to that shown in panel
b (Magnification,180). Figure is representa-
tive of N  3 rats examined for each group.
bined therapy. Kidneys from controls had very weak or Here, we took advantage of the severe model of accel-
no signal (Fig. 7a). In contrast, a strong perinuclear and erated PHN in the rat [26], and started the treatment
cytoplasmic signal was associated mainly with tubular when the animals had heavy and persistent proteinuria
epithelial cells in the kidneys of PHN rats given vehicle and already measurable renal lesions, partly resembling
(Fig. 7b). Positive MCP-1 mRNA staining also was pres- advanced phases of human renal disease. We found that
ent in cells located in the interstitium, partly in apparent lisinopril at a conventional antihypertensive dose (40
association with infiltrating inflammatory cells. Con- mg/L) actually normalized blood pressure, but never-
versely, the signal remained low in the kidneys of rats theless uniformly failed to ameliorate proteinuria, renal
treated with lisinopril plus simvastatin (Fig. 7c). No stain- function, and structural lesions. The lack of effect of the
ing was detected in kidney sections from PHN rats plus treatment given late in the course of disease, even in those
vehicle incubated with the corresponding sense MCP-1 rats that received up to 400 mg/L of the ACE inhibitor,
probe (Fig. 7d). contrasts with findings where earlier treatment (7 days
after disease induction) had effective antiproteinuric
properties and lessened tubulointerstitial inflammationDISCUSSION
and scarring [4].
Angiotensin converting enzyme inhibitors have a po-
The identification of multiple cellular mechanisms oftent antiproteinuric and renoprotective action. In rat
injury has led to the concept of simultaneously inter-models, ACE inhibitors prevented proteinuria and se-
rupting disparate events to slow progression of protein-vere structural injury including interstitial lesions, effects
uric glomerulopathies [26, 38–41]. Given the availablethat along with blocking of angiotensin II (Ang II) me-
evidence that statins, independently of their cholesterol-diated mechanisms of injury, can be attributed to the
lowering effect, also may influence pathways involved indrug’s ability to limit excess protein traffic across the
inflammatory and fibrogenic processes [19], we assessedaltered glomerular barrier and its deleterious conse-
the effect of combining lisinopril with simvastatin. Firstquences [6]. This was almost invariably achieved when
we wanted to assess whether statin by itself could affecttherapy started early after glomerular insult [7–10]. In
progression in this model. In fact, simvastatin alone onlyproteinuric patients, the greater the effect of ACE inhibi-
had a quite limited effect on proteinuria and interstitialtor on proteinuria, the greater the rate of reduction of
inflammation, not enough to affect lesion progression toprogressively declining GFR [32]. However, a delayed
any significant degree. However, the combined adminis-administration of ACE inhibitor may not be sufficiently
tration of lisinopril and simvastatin had a remarkableeffective either in animal models [33–35], or, more im-
antiproteinuric and renoprotective effect. It even de-portantly, in patients possibly referred late in the course
of their disease [36, 37]. creased urinary protein excretion with respect to pre-
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treatment values in 50% of rats, and maintained stable the podocytes [46]. On the other hand, it has been re-
cently reported that statins have the capability to preventlevels over time in almost all other animals. As a result, at
10 months the mean value of proteinuria was significantly the loss of the anionic sites in the GBM, as documented
in 5/6 nephrectomized rats fed a high-cholesterol dietlower in the combination group than in vehicle and lis-
inopril groups. Combined therapy afforded remarkable (Suzuki T, personal communication) that may account
for the additional antiproteinuric effect when combinedprotection against renal function deterioration, and also
limited glomerular and tubulointerstitial damage. with lisinopril. The possibility that the superior protec-
tive effect of combined drugs may be ascribed to antipro-To date, very few studies have evaluated the effect of
combination of ACE inhibitor and statin in comparison teinuric action rather than to effects on blood pressure
is further supported by evidence that in the same modelwith single drug therapy in progressive renal disease. In
the rat model of puromycin-induced nephrotic syn- of the present study, despite keeping blood pressure
within levels comparable to those achieved by the com-drome, it was shown that treatment with enalapril (from
2 to 8 weeks after puromycin injection) did not affect bined therapy, the antihypertensive agent lacidipine
failed to substantially limit proteinuria and renal damagethe course of the disease, whereas lovastatin improved
renal function and structure [42]. The combined treat- in contrast to early lisinopril treatment [47].
A major finding in the present study is that the com-ment resulted in further reduction of glomerulosclerosis
and urinary protein excretion. It was suggested that lov- bined therapy, in addition to maintaining proteinuria to
stable levels, protected against tubulointerstitial eventsastatin promotes the improvement in function and histol-
ogy at least in part by its action of lowering circulating that mediate progression of renal damage. Reports have
clearly demonstrated that statins additionally interferelipids in these rats, or by directly reducing proliferation
of mesangial cells, while enalapril could act by lowering with intracellular signaling pathways and transcription
of genes involved in inflammation and fibrogenesis [19].protein excretion. In another study, rats with 5/6 ne-
phrectomy were partially protected by enalapril or lova- In a rat model of Ang II-induced renal injury, treatment
with cerivastatin reduced renal MAP kinase activationstatin alone (given from 8 to 16 weeks after renal ablation)
against progressive glomerulosclerosis, and the disease and inhibited activator protein-1 (AP-1) and NF-B ac-
tivity, thereby limiting leukocyte adhesion and infiltra-was almost halted by a combination of the two drugs
[43]. At variance with the above models, statin alone tion and ameliorating end-organ damage, independently
of changes in serum cholesterol or blood pressure [48].had a minimal effect against high serum cholesterol of
PHN rats. However, a significant correlation was found Here, since evidence is available that statins can reduce
expression and production of MCP-1 in vitro [22], we fo-between proteinuria and serum cholesterol, as evaluated
at 10 months in all the experimental groups. Among rats cused on MCP-1, a NF-B dependent gene, previously
found by us to be overexpressed in the kidney of PHNgiven the combined therapy those with less proteinuria
than before treatment also had their serum cholesterol rats in strict association with increase of proteinuria and
renal NF-B activity [4]. Up-regulation of renal MCP-1kept within the control range. Hence, the amelioration
of proteinuria in these animals may have led to improve- was confirmed in the current study. The high MCP-1
mRNA levels persisted after lisinopril treatment, whereasment of secondary hypercholesterolemia after glomeru-
lar injury in PHN. However, hypercholesterolemia and in rats given simvastatin MCP-1 gene up-regulation was
inhibited by 30% with respect to vehicle. Strikingly, inpresumably changes in the mevalonate pathway may
concur to propagate renal injury [44], and we cannot the kidney of PHN rats treated with lisinopril plus sim-
vastatin, MCP-1 transcript levels were almost completelyformally exclude that reduction in high cholesterolemia
can be interpreted as an additional factor of renal protec- normalized, and interstitial inflammation was signifi-
cantly reduced. Thus, the beneficial effects of combinedtion by combined therapy.
The mechanism(s) by which lisinopril plus simvastatin, therapy against injury can be attributed, at least in part,
to inhibition of MCP-1–dependent interstitial inflamma-when initiated late during the course of renal disease of
PHN, prevented proteinuria from further worsening can tion by simvastatin, which adds to the protection con-
ferred against both the progressive dysfunction of thebe related to the combined drugs’ actions on the function
of the glomerular filtration barrier to proteins. In a previ- glomerular permselective barrier and the consequent
proinflammatory phenotype of tubular cells. In this re-ous study, we found a decrease in the frequency of epi-
thelial filtration slits and increased thickness of the glo- spect, one also can speculate that the molecular mecha-
nisms whereby simvastatin may attenuate tubular cellmerular basement membrane (GBM) in PHN rats. Early
treatment with lisinopril preserved the frequency of epi- activation in this setting relate to the ability of statins to
inhibit NF-B [48, 49].thelial slits and prevented the associated loss of the hy-
draulic permeability of the GBM [45]. Furthermore, In conclusion, the results of this study document that
in a severe model of progressive nephropathy resistantblocking Ang II synthesis or activity preserved in PHN
the expression of the slit diaphragm protein, nephrin, in to ACE inhibitor, combining the ACE inhibitor with a
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progression of established glomerular disease in obese Zucker rats.statin arrests proteinuria and protects from renal func-
Am J Kidney Dis 22:83–89, 1993
tion and structure impairment. The likely targets of the 15. Kim SI, Han DC, Lee HB: Lovastatin inhibits transforming growth
combined drugs’ action are the glomerular permselective factor-1 expression in diabetic rat glomeruli and cultured rat
mesangial cells. J Am Soc Nephrol 11:80–87, 2000dysfunction and, with simvastatin, the secondary pro-
16. Harris KP, Purkerson ML, Yates J, Klahr S: Lovastatin amelio-inflammatory activation of tubular epithelial cells, which rates the development of glomerulosclerosis and uremia in experi-
fosters chronic tubulointerstitial injury. Such an ap- mental nephrotic syndrome. Am J Kidney Dis 15:16–23, 1990
17. Park YS, Guijarro C, Kim Y, et al: Lovastatin reduces glomeru-proach could represent a therapeutic option for patients
lar macrophage influx and expression of monocyte chemoattractantwith advanced renal disease in whom ACE inhibitors protein-1 mRNA in nephrotic rats. Am J Kidney Dis 31:190–194,
alone fail to lower proteinuria and injury to any substan- 1998
18. Yoshimura A, Inui K, Nemoto T, et al: Simvastatin suppressestial extent.
glomerular cell proliferation and macrophage infiltration in rats
with mesangial proliferative nephritis. J Am Soc Nephrol 9:2027–
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